TISIDB

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF00443 Ubiquitin carboxyl-terminal hydrolase
Function	Ubiquitin hydrolase that can remove conjugated ubiquitin from AXIN1 and AXIN2, thereby acting as a regulator of Wnt signaling pathway. Acts as an activator of the Wnt signaling pathway downstream of the beta-catenin destruction complex by deubiquitinating and stabilizing AXIN1 and AXIN2, leading to promote nuclear accumulation of AXIN1 and AXIN2 and positively regulate beta-catenin (CTNBB1)-mediated transcription. Recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of poly-ubiquitin precursors as well as that of ubiquitinated proteins.

> Gene Ontology [ TOP ]
Biological Process	GO:0016055 Wnt signaling pathway GO:0016570 histone modification GO:0016578 histone deubiquitination GO:0016579 protein deubiquitination GO:0030111 regulation of Wnt signaling pathway GO:0030177 positive regulation of Wnt signaling pathway GO:0060070 canonical Wnt signaling pathway GO:0060828 regulation of canonical Wnt signaling pathway GO:0070646 protein modification by small protein removal GO:0071108 protein K48-linked deubiquitination GO:0090263 positive regulation of canonical Wnt signaling pathway GO:0198738 cell-cell signaling by wnt
Molecular Function	GO:0004175 endopeptidase activity GO:0004197 cysteine-type endopeptidase activity GO:0004843 thiol-dependent ubiquitin-specific protease activity GO:0008234 cysteine-type peptidase activity GO:0019783 ubiquitin-like protein-specific protease activity GO:0036459 thiol-dependent ubiquitinyl hydrolase activity GO:0101005 ubiquitinyl hydrolase activity
Cellular Component	GO:0000123 histone acetyltransferase complex GO:0000124 SAGA complex GO:0031248 protein acetyltransferase complex GO:0070461 SAGA-type complex GO:1902493 acetyltransferase complex GO:1905368 peptidase complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-5688426: Deubiquitination R-HSA-392499: Metabolism of proteins R-HSA-597592: Post-translational protein modification R-HSA-162582: Signal Transduction R-HSA-195721: Signaling by Wnt R-HSA-201681: TCF dependent signaling in response to WNT R-HSA-5689880: Ub-specific processing proteases

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between USP34 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of USP34 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of USP34 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.073	0.769
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.028	0.985
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.102	0.925
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.094	0.791
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.333	0.912
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.207	0.957
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.334	0.454
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.468	0.817
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.201	0.929
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.274	0.861
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.944	0.683
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.047	0.296

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of USP34 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	5.9	-5.9	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	33.3	-33.3	0.231
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	22.2	4.1	18.1	0.011
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	22.2	3.4	18.8	0.0106
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	14.3	29.4	-15.1	0.426
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	16.7	-4.2	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	15.4	36.4	-21	0.357
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	22.2	6.2	16	0.53
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	11.1	28.9	0.505
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	7.9	3.7	4.2	0.636
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of USP34. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of USP34. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by USP34. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of USP34. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of USP34 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between USP34 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	USP34
Name	ubiquitin specific peptidase 34
Aliases	KIAA0570; KIAA0729; ubiquitin specific protease 34; deubiquitinating enzyme 34; ubiquitin thioesterase 34; u ......
Chromosomal Location	2p16.1-p15
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting USP34 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse USP34